Strategic Insights into Lupus Therapeutics: Navigating the Treatment Landscape
 |
| Lupus Therapeutics |
Lupus is a chronic autoimmune
disease that causes the immune system to attack healthy tissues and organs in
the body. Systemic lupus erythematosus (SLE), commonly known as lupus, affects
various parts of the body including joints, skin, kidneys, blood cells, brain,
heart and lungs. According to the Lupus Foundation of America, around 1.5
million Americans and at least 5 million people worldwide have a form of lupus.
For years, treatment options for lupus have been limited with corticosteroids
and immunosuppressant drugs being the standard therapy. However, recent
research and clinical trials have uncovered new therapeutic avenues providing
hope to patients living with this debilitating disease.
New Biologic Therapies target
specific components of the immune system
Research has shown that abnormal
activation of B lymphocytes and increased production of autoantibodies and
inflammatory cytokines play a major role in the pathogenesis of lupus. With
better understanding of disease mechanisms, biologic therapies targeting
specific components of the immune system have emerged. Belimumab (Benlysta), a
B-lymphocyte stimulator (BLyS)-specific inhibitor antibody, was the first new
drug approved by the FDA in over 50 years for the treatment of lupus in 2011.
In clinical trials, Belimumab reduced disease flares and improved symptoms when
added to standard therapy. Rituximab, a monoclonal antibody against CD20
antigen present on B cells, has shown efficacy in phase III trials. Other
biologics like Atacicept, which targets BLyS and APRIL cytokines, are being
investigated in late stage clinical studies. These targeted immunotherapies
offer safer options with less severe side effects than conventional drugs.
Complement System inhibitors
address specific pathways
Complement system, part of the
innate immune response, is hyperactive in lupus and its inhibition could reduce
inflammation. Eculizumab, a C5 complement inhibitor, has been effective in
small case studies of lupus patients with persistent disease activity despite
conventional treatments. Lupus nephritis patients treated with Eculizumab in an
open-label trial saw reduced proteinuria levels. Other complement inhibitors in
clinical trials include Ravulizumab (targets C5) and Lifitegrast (inhibits
C3/C5 activation). Blocking specific complement pathways involved in autoimmunity
holds promise for controlling disease while sparing beneficial immune
functions. These complement inhibitors represent a novel approach with
potential to replace current standard of care therapies.
Therapeutic vaccines aim to restore
immune tolerance
Loss of immune tolerance to
self-antigens is central to the pathogenesis of lupus. Therapeutic vaccines aim
to induce antigen-specific regulatory T cells to re-establish tolerance against
autoantigens. One such approach is Lupuzor/LupusVax consisting of
autoantigen-presenting dendritic cells. A phase IIb trial showed Lupuzor
reducing anti-dsDNA antibodies and improving clinical measures. Iarlo, an oral
vaccine containing autoantigens linked to cholera toxin B subunit, completed phase
I/II testing showing good tolerability and immune modulation. Other
antigen-specific approaches for lupus
therapeutics in clinical development include oral and intralymphatic
injections of apoptotic cell mimics like Annexin-V. Therapeutic vaccines offer
a personalized treatment strategy with durable effects and less side effects
than global immunosuppression.
Stem cell transplantation offers
hope of remission
High-dose immunosuppression
followed by autologous hematopoietic stem cell transplantation (AHSCT) can
induce prolonged remissions in severe refractory cases of SLE. In AHSCT, a
patient's own stem cells are collected, stored and reinfused after high-dose
chemotherapy+/-radiotherapy intended to "reset" the immune system. A
recent multicenter trial showed 77% of patients achieving drug-free remission
at 2 years after AHSCT. While AHSCT carries risks of treatment-related
mortality, it provides prospect of cure for selected patients. Less intense
approaches combining immunosuppression with low-dose conditioning and stem
cells from family donors (allogeneic HCT) are being assessed aiming for similar
benefits with reduced toxicity. As understanding improves, stem cell therapy
may become available to appropriate patients failing multiple lines of
treatment.
Novel Oral Treatments address
unmet medical needs
Despite advances, currently
available drugs are inadequate for many patients enduring disease flares, organ
damage and debilitating fatigue. New oral treatments are designed to address
unmet needs through safer and more convenient administration. Anifrolumab, a
type I IFN receptor antagonist, has shown to reduce flares and steroid use in
phase III trials. Belamaf, a selective inhibitor of Bruton's tyrosine kinase
involved in B cell and myeloid cell signaling, achieved its main efficacy goals
versus placebo in phase III trials enrolling over 1000 lupus patients
worldwide. Bruton's tyrosine kinase (BTK) represents a promising new target for
oral treatment of lupus. Other novel oral candidates undergoing active
investigation include inhibitors of IL-6, Protein Kinase C-θ, IRAK1/4 kinases
and LFA-1 integrin involved in leukocyte migration. Convenient oral therapies
have potential to improve quality of life while easing disease management
challenges for lupus patients.
Get More Insights Here
https://www.newsanalyticspro.com/integrating-therapeutics-for-better-outcomes/
Comments
Post a Comment